Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
00:31:02 EDT Mon 21 Apr 2025
Enter Symbol
or Name
USA
CA



Forgot password?
Trouble logging in?
Login ID:
Password:
Save

C:RVV - Revive Therapeutics Ltd. - https://www.revivethera.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
RVV - C  656.50.03·0.03599.00.03    0.035  0.005Apr 17Apr 1015 min RT 2¢
CSE - C656.50.03·0.03599.00.03    0.035  0.005Apr 1715 min

Recent Trades - All 0 today
Time ETExPriceChangeVolumeBuyerSellerMarkers
        
        
        
        
        
        
        
        
        
        

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolPriceTypeHeadline
2025-04-10 13:52C:RVV0.02News ReleaseRevive to study bucillamine as cancer treatment
2025-04-01 16:35C:RVV0.015News ReleaseRevive agrees to buy Diagnamed's molecular hydrogen IP
2025-03-19 17:28C:RVV0.01News ReleaseRevive shareholders approve all matters at AGSM
2025-03-03 19:00C:RVV0.01News ReleaseRevive to buy molecular hydrogen rights from Diagnamed
2025-02-28 18:44C:RVV0.01SEDAR Interim Financial StatementsSEDAR Interim Financial Statements
2025-02-28 18:44C:RVV0.01SEDAR Interim MD & ASEDAR Interim MD & A
2025-02-03 21:30C:RVV0.01News ReleaseRevive to complete Bucillamine study in February
2025-01-08 16:41C:RVV0.005News ReleaseRevive Therapeutics talks bucillamine research study
2024-11-29 21:02C:RVV0.01SEDAR Interim MD & ASEDAR Interim MD & A
2024-11-29 20:36C:RVV0.01SEDAR Interim Financial StatementsSEDAR Interim Financial Statements
2024-11-12 15:31C:RVV0.01News ReleaseRevive talks BMC article on psilocybin research study
2024-10-31 15:17C:RVV0.01News ReleaseRevive expects bucillamine study results by year-end
2024-10-28 15:53C:RVV0.01SEDAR MD & ASEDAR MD & A
2024-10-28 15:47C:RVV0.01SEDAR Audited Annual Financial StatementsSEDAR Audited Annual Financial Statements
2024-09-18 11:52C:RVV0.01News ReleaseRevive Therapeutics to focus on bucillamine
2024-08-28 10:21C:RVV0.015News ReleaseRevive hopes to complete bucillamine study in October
2024-07-02 15:59C:RVV0.01News ReleaseRevive begins bucillamine study on nerve agent exposure
2024-06-12 12:14C:RVV0.02News ReleaseRevive receives FDA feedback on Bucillamine study
2024-06-10 11:22C:RVV0.02News ReleaseRevive receives FDA feedback for diagnostic device
2024-05-31 01:25C:RVV0.025SEDAR Interim MD & ASEDAR Interim MD & A